EUVIMEDEUVIMED entdecken
Crossref

Baseline Tumor Proliferation and Ki-67 Are Associated With Pathological Response to Neoadjuvant Chemoimmunotherapy in Non–Small Cell Lung Cancer

Jianghua Wu, Wei Sun, Xinying Liu, Xin Yang, Luning Mao, Chenglong Wang, Xinting Diao, Xiaozheng Huang, Dongmei Lin

Modern Pathology · 2026-08 · 39 (8) · 101028

DOI: 10.1016/j.modpat.2026.101028 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2026-08. Verfasst von Jianghua Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Pathology, Peking University Cancer Hospital and I…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Ki-67 Antigen, Lung Neoplasms, Cell Proliferation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heterogeneity in the pathological response to neoadjuvant chemoimmunotherapy underscores the need for predictive biomarkers in resectable non-small cell lung cancer (NSCLC). This study identified baseline molecular features-particularly tumor proliferation signatures-associated with pathological response. Two retrospective cohorts (test, n = 81; validation, n = 107) of patients with NSCLC who received neoadjuvant chemoimmunotherapy were analyzed. Bulk RNA sequencing was performed on baseline biopsies from the test cohort, with immunohistochemistry (IHC) for PD-L1 and Ki-67 in both cohorts. Outcomes included major pathological response (MPR), pathological complete response (pCR), and event-free survival. In the test cohort, transcriptomic analysis showed that responders had significant upregulation of proliferation-related genes (eg, TP63, SOX2, NTRK2, and HMGA2) and activation of proliferation signatures (eg, chromosomal instability signature and core embryonic stem cell-like module), without activation of canonical immune-inflamed pathways. PD-L1 expression had limited predictive value (area under the curves [AUCs], 0.56-0.59 for MPR and 0.52-0.54 for pCR). In contrast, proliferation markers demonstrated higher performance: MKI67 messenger RNA predicted both MPR and pCR with an AUC of 0.71, and the Ki-67 IHC index yielded AUCs of 0.71 for MPR and 0.64 for pCR. The predictive value of the Ki-67 IHC index was validated in the independent cohort, with AUCs of 0.74 for MPR and 0.70 for pCR, and this association was generally consistent across squamous cell carcinoma and adenocarcinoma. A Ki-67 index ≥50% was significantly correlated with improved event-free survival in both cohorts (both Ps < .05). These findings indicate baseline tumor proliferation, particularly MKI67/Ki-67, as predictors of pathological response in NSCLC patients receiving neoadjuvant chemoimmunotherapy, supporting its potential clinical utility for patient selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungKi-67 AntigenLung NeoplasmsCell ProliferationBiomarkers, TumorHumansNeoadjuvant TherapyFemaleMaleMiddle AgedRetrospective StudiesAgedPathologic Complete ResponseImmunotherapy

Stichwörter der Autor:innen

Ki-67PD-L1neoadjuvant chemoimmunotherapynon–small cell lung cancerproliferation signature

Substanzen

Ki-67 AntigenBiomarkers, TumorMKI67 protein, human

Autor:innen und Institutionen

  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Pathology, Peking University Cancer Hospital and Institute, Beijing, China; Department of Pathology, School of Basic Med…
  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Pathology, Peking University Cancer Hospital and Institute, Beijing, China.
  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Pathology, Peking University Cancer Hospital and Institute, Beijing, China. Electronic address: lindm3@163.com.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wu, J., Sun, W., Liu, X., Yang, X., Mao, L., Wang, C., Diao, X., Huang, X., & Lin, D. (2026). Baseline Tumor Proliferation and Ki-67 Are Associated With Pathological Response to Neoadjuvant Chemoimmunotherapy in Non–Small Cell Lung Cancer. Modern Pathology, 39(8), 101028. https://doi.org/10.1016/j.modpat.2026.101028

Vancouver

Wu J, Sun W, Liu X, Yang X, Mao L, Wang C, et al. Baseline Tumor Proliferation and Ki-67 Are Associated With Pathological Response to Neoadjuvant Chemoimmunotherapy in Non–Small Cell Lung Cancer. Modern Pathology. 2026;39(8):101028. doi:10.1016/j.modpat.2026.101028

BibTeX
@article{Wu2026,
  author = {Wu, Jianghua and Sun, Wei and Liu, Xinying and Yang, Xin and Mao, Luning and Wang, Chenglong and Diao, Xinting and Huang, Xiaozheng and Lin, Dongmei},
  title = {Baseline Tumor Proliferation and Ki-67 Are Associated With Pathological Response to Neoadjuvant Chemoimmunotherapy in Non–Small Cell Lung Cancer},
  journal = {Modern Pathology},
  year = {2026},
  volume = {39},
  number = {8},
  pages = {101028},
  doi = {10.1016/j.modpat.2026.101028}
}
Kostenlos starten →